Armata Q1 loss widens to $11.3M; positive Ph1b/2a data for AP-PA02; closes $30M convertible

Armata Pharmaceuticals, Inc.

2023-Q1 EPS reported -$0.40

Positive topline data from AP-PA02 Ph1b/2a in cystic fibrosis; first patient dosed in Phase 2 NCFB study.
AP-SA02 advanced: second cohort dosed in Staphylococcus aureus bacteremia Ph1b/2a; PJI study start-up activities.
Closed $30M secured convertible credit agreement with Innoviva (largest shareholder) to fund trials and manufacturing.
Q1 loss from operations $(11.3)M vs $(8.8)M a year ago; cash $25.1M vs $14.9M at Dec 31, 2022.
Grant revenue $0.8M from MTEC/DoD; $16.3M total grant funding expected for AP-SA02 program.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Armata Pharmaceuticals, Inc. reported financial results for the quarter ended March 31, 2023.

Period: the quarter ended March 31, 2023
Result: reported results

Exact text from the filing

On May 11, 2023, Armata Pharmaceuticals, Inc. (the “Company”) announced its financial results for the quarter ended March 31, 2023, in the press release furnished hereto as Exhibit 99.1.

View on SEC.gov

36 earnings releases filed in the last 30 days. Browse all earnings releases →

Armata Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-23-059297

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.